The Reversal
Eli Lilly closed Friday at roughly $1,105, up about 4.3% on the day, after CVS Health announced it would restore coverage for weight loss injection Zepbound and add the oral pill Foundayo to its commercial formularies. The move gives Lilly access to the roughly 25 to 30 million Americans covered through CVS Caremark's standard formulary template.
CVS dropped Zepbound from its formularies last July after negotiating a better price from Novo Nordisk for rival drug Wegovy. That decision locked Lilly out of the largest pharmacy benefit manager in the country for nearly a year. Now both drugs are coming back as co-preferred options, and they are bringing a new one with them.
Why the Pill Matters
Foundayo, Lilly's oral GLP-1 drug, received FDA approval on April 1 and will be covered through CVS Caremark starting Monday, June 1. Eligible patients with commercial coverage can get it for as little as $25 a month.
The convenience factor is Foundayo's competitive edge. It can be taken at any time of day without food or water restrictions. Novo's Wegovy pill, approved in December 2025, requires specific dosing windows and dietary considerations typical of oral semaglutide.
Clinical results show the Wegovy pill delivers higher average weight loss, roughly 16.6% versus 12% for Foundayo. But convenience drives adherence, and adherence drives real-world outcomes. A pill patients actually take every day can outperform one they skip. With this decision, all three of America's largest pharmacy benefit managers now cover Lilly's full obesity portfolio for the first time. Zepbound returns to CVS formularies on October 1.
Two Stocks, Two Trajectories
The stock performance tells the competitive story clearly. Lilly trades near $1,105 with a market capitalization above $1 trillion and a forward P/E of roughly 29 times. The company recently raised its full-year revenue guidance to between $82 billion and $85 billion. Wall Street analysts project Foundayo alone could generate between $1.5 billion and $2.8 billion in revenue this year, ramping toward estimated peak annual sales that some firms see exceeding $40 billion. The consensus price target sits around $1,225, with 90% of covering analysts rating the stock a buy.
Novo Nordisk tells the other side. The ADR trades around $45, down roughly 44% from its 52-week high near $81. The forward P/E has compressed to around 14 times. Novo still holds roughly 65% of new GLP-1 prescriptions in the United States, but the company guided for adjusted sales and profit to decline between 4% and 12% this year.
The pricing dynamics explain the divergence. When CVS dropped Zepbound last year, Novo had to offer steep discounts to win that exclusive formulary position. Now that CVS is bringing Lilly back as co-preferred, those exclusivity discounts no longer buy a monopoly. Novo is giving up margin without locking in market share.
What to Watch From Here
Foundayo's Q2 revenue, reported with Lilly's next earnings, will show whether the launch trajectory matches the $2 billion-plus annual forecasts. Early launch data from April was limited by supply ramp. The CVS formulary addition starting Monday removes the largest remaining distribution bottleneck.
Zepbound's October 1 reinstatement at CVS creates a second catalyst in the same year. That makes the back half of 2026 a two-stage formulary unlock for a product already generating billions in quarterly revenue.
Novo's response matters, too. The company has the clinical data advantage with the Wegovy pill. But a 44% decline from the 52-week high suggests the market is pricing in structural share loss that better trial results alone may not reverse. Novo trades at roughly half Lilly's forward earnings multiple. That gap either reflects a buying opportunity for contrarians or a market that has already made its judgment.
